Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$5.29-0.8%$4.18$2.57▼$7.00$289.95M1.86545,090 shs157,806 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-2.20%-2.02%+30.64%+64.51%+13.89%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix1.4648 of 5 stars3.50.00.00.02.91.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix3.00Buy$13.00144.82% UpsideCurrent Analyst RatingsLatest CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024CRMDCorMedixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.004/9/2024CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/13/2024CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.001/31/2024CRMDCorMedixTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$60K4,850.69N/AN/A$1.28 per share4.15Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$46.34M-$0.92N/AN/AN/AN/A-72.31%-63.97%5/20/2024 (Estimated)Latest CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRMDCorMedix-$0.21-$0.26-$0.05-$0.26N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A6.976.78OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix8254.81 million52.84 millionOptionableCRMD HeadlinesSourceHeadlineCorMedix product 'DefenCath' gains CMS transitional payment statusinvesting.com - April 20 at 9:09 PMCorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCathfinanznachrichten.de - April 20 at 6:24 PMCorMedix Shares Rise 6% After DefenCath Meets Payment Criteriamarketwatch.com - April 19 at 12:25 PMCorMedix Inc. Announces CMS Grants TDAPA to DefenCathglobenewswire.com - April 19 at 8:30 AMCorMedix Inc. (NASDAQ:CRMD) Short Interest Up 6.2% in Marchamericanbankingnews.com - April 18 at 2:38 AMShort Interest in CorMedix Inc. (NASDAQ:CRMD) Increases By 6.2%marketbeat.com - April 16 at 12:23 PMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMCorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)globenewswire.com - April 15 at 8:30 AMCRMD Apr 2024 7.000 callfinance.yahoo.com - April 15 at 12:28 AMCRMD Apr 2024 8.000 putfinance.yahoo.com - April 15 at 12:28 AMWall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Knowzacks.com - April 11 at 10:55 AMCorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conferencefinance.yahoo.com - April 11 at 8:44 AMCorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conferenceglobenewswire.com - April 11 at 8:30 AMCorMedix (NASDAQ:CRMD) Receives Market Outperform Rating from JMP Securitiesmarketbeat.com - April 9 at 8:49 AMAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)markets.businessinsider.com - April 9 at 7:36 AMCorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLCglobenewswire.com - April 8 at 8:30 AMBreakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD)finance.yahoo.com - April 2 at 12:24 PMCorMedix Inc. to Present at the Needham Annual Healthcare Conferencefinance.yahoo.com - March 27 at 9:34 AMCRMD Apr 2024 6.000 putfinance.yahoo.com - March 16 at 9:19 AMCRMD Apr 2024 3.000 putfinance.yahoo.com - March 16 at 8:46 AMCRMD Apr 2024 3.000 callfinance.yahoo.com - March 16 at 8:16 AMCorMedix Inc. (NASDAQ:CRMD) CEO Joseph Todisco Purchases 13,561 Sharesinsidertrades.com - March 15 at 11:42 AMTruist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)markets.businessinsider.com - March 13 at 8:41 PMAnalysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)markets.businessinsider.com - March 13 at 1:26 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorMedixNASDAQ:CRMDCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.